Antibiotics fight infections caused by bacteria. They should not be used to treat infections caused by viruses (such as the flu) or types of fungi, which include yeasts and molds.
Site Search
Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
Managing cystic fibrosis can feel overwhelming at times — but we’re here to help. Learn how to navigate life with CF.
Tomorrow's Leaders is a community of young professionals who come together to make a difference for those living with cystic fibrosis while growing their network, making personal connections, and developing professional skills.
A virtual program for current and recent college students who want to continue building new leadership, advocacy, and fundraising skills to make a difference on their campuses and beyond.
Vascular access devices, or PICCs and ports, allow repeated and long-term access to the bloodstream for frequent or regular administration of drugs, like intravenous (IV) antibiotics.
Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021.